We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Medical

TC BioPharm Limited

Status: Active

Dec 10th 2020 - Jan 9th 2021

TC BioPharm is an immunotherapy company. It has used its patented technology to harness the power of a particular part of the immune system, Gamma Delta T-cells (GDT), to negate cancer cells in the human body. TC BioPharm has treated terminally ill patients with acute myeloid leukaemia in approved clinical trials garnering positive responses from multiple patients. The company has received regulatory approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to run a COVID-19 clinical trial to address the global pandemic. TC BioPharm aims to use its current technology to provide a frozen product that can be manufactured cost-effectively and distributed globally. The company has already raised over £7 million in the last 15 months. It will use the investment to take its clinical trials forward in COVID-19 and cancer.

read more read less

TC BioPharm Limited Rating Review

Pitch rating powered by CROWDRATING

Rated on 23/12/2020

Pitch Rated

59%

Insufficient Data

Management

90%

Product

87%

Investment

UNRATED*

* Section unrated owing to insufficient or incomplete information available at the time of rating.

Log in to view amount pledged

    Log in to view target

    £107,284,609
    pre-money valuation

    1.10%
    equity available

    682
    investors

    £2,570
    pledge per investor

    01/07/2013
    incorporated 11 years

    £43.00
    share price

    Previous Funding rounds
    11 Mar 24 Crowdcube £1,753,067 / 146% 59.00%
    News

What the ratings mean

  • 49% and under
    We suggest potential investors carry out further study of their own
    50-64%
    Room for improvement
    65-79%
    Worth considering
    80%+
    Gold rating, our highest rating

RISK WARNING - The ratings are based on the information provided in the fund raiser’s pitch deck, business plans and financial forecasts which have appeared on a FCA regulated crowdfunding site. Where possible we validate the business plan to public sources such as LinkedIn, Companies House, Credit Agencies and internet searches. We cannot guarantee the information is correct. The ratings report takes no account of the investors/ individual circumstances. Do your own due diligence and get professional advice before investing. Your capital is at risk when investing in private companies.

Login to view the full report

Management 90%

Skills 91%
The management team at TC BioPharm Limited includes skilled professionals with expertise in management, bit-technology, marketing, and finance. It consists of an experienced Founder/Chief Executive Officer, Founder/Chief Operating Officer, Chief Technical Officer, Chief Financial Officer, Scientific and Medical Director, and Senior Clinical Director. The Founder/Chief Executive Officer is a senior executive with expertise in Biotechnology, Clinical Research, Entrepreneurship and Pharmaceutical Industry. He also has prior experience of working at the same stage of business growth. He has also recently been presented with the 'Scottish Life-Sciences Entrepreneurial Business Leadership' award 2016-17. The Founder/Chief Operating Officer is competent in Manufacturing of Cellular Therapies, Technical Transfer and Biologic Process Development and Building, Designing Commission of GMP production facilities. The Chief Financial Officer is skilled in Mergers and acquisitions (M&A), Initial public offering, Repositioning, and restructurings. The Chief Technical Officer specialises in business strategy, due diligence, licensing, pharma for pre-clinical and clinical-stage assets, drug development and discovery.

0 comments

Log in to comment


Funding progress

Log in to view funding progress.


Log in to view amount pledged

    Log in to view target

    £107,284,609
    pre-money valuation

    1.10%
    equity available

    682
    investors

    £2,570
    pledge per investor

    01/07/2013
    incorporated 11 years

    £43.00
    share price

    Previous Funding rounds
    11 Mar 24 Crowdcube £1,753,067 / 146% 59.00%
    News
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph